News coverage about Haemonetics (NYSE:HAE) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Haemonetics earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 46.2080722776484 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several research firms have commented on HAE. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 7th. TheStreet cut Haemonetics from a “b” rating to a “c+” rating in a report on Monday, August 20th. Morgan Stanley lifted their price target on Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, August 8th. Barrington Research lifted their price target on Haemonetics from $90.00 to $118.00 and gave the company an “outperform” rating in a report on Thursday, August 9th. Finally, Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $105.00 price target for the company in a report on Tuesday, June 12th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $98.33.
Top 5 Medical Stocks To Buy For 2019: Orchid Island Capital, Inc.(ORC)
Advisors' Opinion:- [By Logan Wallace]
Orchid Island Capital (NYSE: ORC) and Alexandria Real Estate Equities (NYSE:ARE) are both finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.
- [By Paul Ausick]
Orchid Island Capital Inc. (NYSE: ORC) fell about 9.7% to post a new 52-week low of $7.85 Thursday after closing at $8.69 on Wednesday. The 52-week high is $12.60. Volume of about 5.2 million was nearly 5 times the daily average of around 1.1 million. The company lowered its monthly dividend by 3 cents last night.
- [By Shane Hupp]
One Liberty Properties (NYSE: ORC) and Orchid Island Capital (NYSE:ORC) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
Top 5 Medical Stocks To Buy For 2019: Aclaris Therapeutics, Inc.(ACRS)
Advisors' Opinion:- [By Max Byerly]
Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
- [By Stephan Byrd]
Headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aclaris Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.9638334424702 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Top 5 Medical Stocks To Buy For 2019: Ultragenyx Pharmaceutical Inc.(RARE)
Advisors' Opinion:- [By Shane Hupp]
Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Todd Campbell]
A Genentech alumnus, Conner was previously vice president of clinical science at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotech that has successfully developed therapies for rare and ultrarare diseases. Prior to that, he was senior medical director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), another biotech company that's successfully developed drugs for rare diseases.
- [By Shane Hupp]
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Director Matthew K. Fust sold 6,319 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The shares were sold at an average price of $72.00, for a total value of $454,968.00. Following the transaction, the director now owns 8,750 shares of the company’s stock, valued at $630,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
- [By Shane Hupp]
These are some of the media headlines that may have effected Accern’s scoring:
Get Ultragenyx Pharmaceutical alerts: Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.
Top 5 Medical Stocks To Buy For 2019: Lazard Global Total Return and Income Fund(LGI)
Advisors' Opinion:- [By Ethan Ryder]
Headlines about Lazard Global Total Return & Income Fund common stock (NYSE:LGI) have been trending somewhat negative recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Lazard Global Total Return & Income Fund common stock earned a news sentiment score of -0.13 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.0546102091578 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Top 5 Medical Stocks To Buy For 2019: Empire Resorts Inc.(NYNY)
Advisors' Opinion:- [By Stephan Byrd]
Wendys (NASDAQ: WEN) and Empire Resorts (NASDAQ:NYNY) are both retail/wholesale companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
No comments:
Post a Comment